Apyx Medical reports preliminary Q4 revenue $12.1-12.5M (-26-28% YoY); full year $44-44.4M (-8-9%)

Apyx Medical Corp

2022-FY EPS reported -$0.67 revenue$44,510,000

Advanced Energy rev Q4 $10.1-10.5M (-30-33% YoY); OEM rev $2.0M (+12% YoY).
Full year Advanced Energy $36.4-36.8M (-14-15%); OEM $7.6M (+37%).
CEO cites continued disruption from FDA Medical Device Safety Communication.
Expects 2023 Advanced Energy sales growth >35% YoY; plans to submit 510(k) for new indication by Jan 2023.
Implementing expense cuts to improve cash flow; evaluating options for liquidity enhancement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.5

Apyx Medical Corp reported preliminary financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: preliminary results

Exact text from the filing

On January 10, 2023, Apyx Medical Corporation (the "Company") issued a press release reporting on its preliminary revenue results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Apyx Medical Corp filing history →

Source: SEC EDGAR

accession 0000719135-23-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.